-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx Pharmaceutical And Its Partner Mereo Biopharma's Phase 3 Orbit And Cosmic Studies For Setrusumab (UX143) In Osteogenesis Imperfecta Did Not Achieve Statistical Significance Against Reduction In Annualized Clinical Fracture Rate Compared To Placebo Or Bisphosphonates, Respectively

Benzinga·12/29/2025 13:34:33
Listen to the news
  • Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)
  • Both studies achieved the secondary endpoint of improvements in bone mineral density with strong statistical significance
  • Ultragenyx will implement significant expense reductions